Anlon Healthcare Reports Quarterly Results; Board Approves Strategic Share Swap for API Acquisitions

Anlon Healthcare Reports Quarterly Results; Board Approves Strategic Share Swap for API Acquisitions​

Anlon Healthcare Limited has announced its unaudited consolidated and standalone financial results for the quarter ending June 30, 2026. In a significant strategic move approved by the Board of Directors, the company also authorized a share swap arrangement intended to acquire two key entities in the pharmaceutical sector.

The Board meeting, held on July 30, 2026, reviewed and approved the operational outcomes alongside authorizing senior management to execute the acquisition. The management was given authority for this strategic transaction involving Apiqo Organics Private Limited (AOPL) and Bizotic LifeScience Private Limited (BLPL).

The proposed share swap involves exchanging company equity shares—issued on a preferential basis for consideration other than cash—for ownership in both AOPL and BLPL. The acquisition aims to establish these entities as wholly-owned subsidiaries, with the company planning to acquire 32.52% of AOPL and 43.33% of BLPL from their current shareholders.

Financial Highlights for Q1 FY2026-27​

Anlon Healthcare Limited demonstrated strong financial performance across both consolidated and standalone operations during the quarter ended June 30, 2026. The company is a research-intensive manufacturer of Active Pharmaceutical Ingredients (APIs) and drug intermediates, and its entire operations are managed as one integrated business segment.

Consolidated Financial Performance (Q1 FY2026-27)
Total Income for the quarter stood at 8,762.23 lakhs, up from 5,090.31 lakhs in the previous quarter, and compared to 3,330.89 lakhs in Q1 FY2025-26. The company reported a Profit before tax of 1,365.99 lakhs, leading to a Profit after tax attributable to the owners of the company of 828.14 lakhs. Total Comprehensive Income for the period was 826.25 lakhs.

Standalone Financial Performance (Q1 FY2026-27)
The standalone results showed Revenue From Operations of 3,097.56 lakhs. The company generated a Total Income of 3,103.52 lakhs for the quarter. After accounting for all expenses—including Cost of materials consumed (2,694.05 lakhs), Employee benefits expense (152.07 lakhs), and Other expenses (294.04 lakhs)—the company reported a Profit before tax of 590.37 lakhs. This resulted in a Profit after tax for the period of 479.71 lakhs, with a Basic Earnings Per Share (EPS) of 0.09.

A detailed comparison of key metrics between the current and previous periods is provided below:

Status of IPO Proceeds Utilization​

Regarding previous fundraising, a statutory auditor's certificate covering the quarter ended June 30, 2026, confirmed the utilization status of proceeds received from the Initial Public Offer (IPO). The company is listed on both NSE under 'AHCL' and BSE under code 544497.

The monitoring agency report stated that there was no unutilized balance of IPO Proceeding as of this certificate date. The total committed funds for objects monitored included:

• Funding capital expenditure requirements: 12,103.00 lakhs
• Offer Expense: 1,513.05 lakhs

Management confirmed in the report that all funds raised through the IPO have been fully utilized in accordance with the objectives of the issue during the period from April 01, 2026, to June 30, 2026.

AHCL Stock Price Movement​

As of 11:53 AM, Anlon Healthcare Limited is slipping by 1.26% in live trading, with shares currently hovering around ₹15.68 after shedding ₹0.20 against the previous close. The equity has seen a significant trading day thus far, with over 2.27 million shares transacted during this volatile market session.